CFO Beat
  • Accounting & Tax
  • Credit & Capital
  • GRC
  • Strategy
  • Technology
  • HR
No Result
View All Result
CFO Beat
  • Accounting & Tax
  • Credit & Capital
  • GRC
  • Strategy
  • Technology
  • HR
No Result
View All Result
CFO Beat
No Result
View All Result
CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits

CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits

April 17, 2019
Post on LinkedinShare on TwitterShare on Facebook

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed the previously announced sale of $5.4 million of NOL tax benefits to two unrelated, profitable New Jersey corporations through the New Jersey Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2018. As a result, the Company has received approximately $5.1 million in cash from the sale of these NOL tax benefits.

“We are pleased to have closed on this transaction,” said Khoso Baluch, CorMedix CEO. “The funding bolsters our cash runway as we continue to move the Neutrolin® development program forward.”

The New Jersey Technology Business Tax Certificate Transfer (NOL) program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 U.S. employees (including parent company and all subsidiaries) to sell a percentage of net operating losses and research and development (R&D) tax credits to unrelated profitable corporations. NOLs and R&D tax credits may be sold for at least 80 percent of their value, up to a maximum lifetime benefit of $15 million per business. This allows qualifying technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund growth and operations, including research and development or other allowable expenditures.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Latest Articles

Data Catalogs Essential for Data Governance and Insights but Under Deployed

Data Catalogs Essential for Data Governance and Insights but Under Deployed

August 6, 2019

Emailage and Featurespace Partner to Tackle Application Fraud

August 5, 2019

Olin Announces $100 Million Accelerated Share Repurchase

August 5, 2019

Microchip Enters Memory Infrastructure Market

August 5, 2019

Combatting Future Security Threats of Quantum Computing

August 5, 2019

Loparex Acquired by Pamplona Capital Management

August 5, 2019
Advertisement BannerAdvertisement BannerAdvertisement Banner

Editor's Picks

Combatting Future Security Threats of Quantum Computing

August 5, 2019

Loparex Acquired by Pamplona Capital Management

August 5, 2019

Unisys to Exchange Approximately $130 Million of Convertible Notes for Stock and Cash

August 2, 2019

Analytics and Data-driven Culture Help Companies Outperform Business Goals

August 1, 2019

Automation Fears are Real: AI Will Affect One in Every Five Jobs in Asia–Eliminating One in Eight

August 1, 2019

Supply Chain Visibility Builds Trust With Consumers

August 1, 2019

American Businesses Are Fixing Healthcare

July 17, 2019

Stay Connected!

Subscribe to CFO Beat

  • Please choose the newsletters you would like to subscribe to.
  • Please enter your work email
LinkedIn Twitter

About Us

  • About Us
  • Contact Us
  • Subscribe
  • Contribute
  • Privacy Policy
  • Terms of Use

Topics

  • Accounting & Tax
  • Credit & Capital Markets
  • Risk & Compliance
  • Strategy
  • Technology
  • Human Capital

Business Beat Media Network:

  • CIO Beat
  • Global Trade Beat
  • Manufacturing Beat
  • Supply Chain Beat
  • Utility Beat

© 2019 Business Beat Media, LLC. All Rights Reserved.

No Result
View All Result
  • Accounting & Tax
  • Credit & Capital Markets
  • Governance, Risk & Compliance
  • Strategy
  • Technology
  • Human Capital
  • About Us
  • Privacy Policy
  • Terms of Use

© 2019 Business Beat Media, LLC. All Rights Reserved.

This site uses cookies. To see how cookies are used, please review our privacy policy. If you agree to our use of cookies, please continue to use our site. Find out more.